- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16.10. | SimBioSys nabs FDA clearance for Nvidia-powered, MRI-derived breast cancer recurrence tool | ||
| 16.10. | 'It's certainly not easy': How are Boston biotechs coping with a shallower pool of seed funding? | ||
| 16.10. | Estuary flows out of stealth with $103M to propel kidney disease gene therapies into clinic | ||
| 16.10. | City goes public with $200M IPO, while Frazier Life Sciences takes biotech-focused SPAC to Nasdaq | ||
| 15.10. | OrbiMed's largest-ever Asian fund contributes to $3B war chest | ||
| 15.10. | Osivax focuses on combo strategy for flu vaccine after phase 2 fail | ||
| 15.10. | AstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugs | ||
| 15.10. | Lakefront Biotherapeutics finally finds buyer for unwanted cell therapy pipeline | ||
| 15.10. | Vanda pauses social anxiety program after ex-Novartis asset flunks phase 3 study | ||
| 15.10. | Iambic goes public with $150M IPO to accelerate clinical development of oncology pipeline | ||
| 15.10. | Why OMass' $310M series C marks 'fantastic milestone' on journey to become 'Britain's Big Biotech' | ||
| 14.10. | Merck KGaA spinout iOnctura touts PI3K delta inhibitor in metastatic eye cancer | ||
| 14.10. | IQVIA, Veeva expand on existing partnership for speedier clinical trials | ||
| 14.10. | Verastem CEO claims RAS drug has 'set a new benchmark' for tricky cancer in early readout | ||
| 14.10. | Deep-pocketed Verdiva axes GLP-1 switching trial over 'market evolution' | ||
| 14.10. | Biomea posts phase 1 data to pitch oral GLP-1 to potential partners, but investors appear unconvinced | ||
| 14.10. | Vir CEO sees 'opportunity to do more deals' after striking $1.9B Gilead pact for dual-masked TCEs | ||
| 14.10. | GSK to lay off over 1,200 roles in Belgium as cost-saving program picks up steam | ||
| 14.10. | Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipeline | ||
| 14.10. | Agilent spends $240M upfront to buy digital pathology specialist Proscia | ||
| 13.10. | Insulet's Omnipod Discover platform sees full market release in US | ||
| 13.10. | BioNTech's mRNA cancer vaccine fails phase 3 test, significantly denting analysts' confidence | ||
| 13.10. | Biotech builder Paragon imports Apogee's top brass after AbbVie buyout | ||
| 13.10. | Roche inks $1.2B deal with China's Rona to enter emerging ALK7 obesity race | ||
| 13.10. | Pfizer inks $500M Enodia pact to join Lilly in emerging protein degrader field |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.